#1 Clinical Trials Search in Europe

Citalopram

This article examines the use of Citalopram, a selective serotonin reuptake inhibitor (SSRI), in various clinical trials. Citalopram, also known by its brand name Celexa, has been studied for its effectiveness in treating conditions such as depression, anxiety disorders, and autism. The trials explore different dosages, formulations, and comparisons with other medications to assess Citalopram’s efficacy, safety, and potential benefits for patients.

Table of Contents

What is Citalopram?

Citalopram is a medication that belongs to a class of drugs called Selective Serotonin Reuptake Inhibitors (SSRIs). It is commonly known by its brand names Celexa[1] and Cipralex[5]. Citalopram is available in tablet form and as a liquid solution[6].

There are two forms of citalopram:

  • Racemic citalopram: This is the standard form, containing both S-citalopram and R-citalopram.
  • Escitalopram: This is a newer version that contains only S-citalopram and is marketed under the brand name Lexapro[8].

What Conditions Does Citalopram Treat?

Citalopram is primarily used to treat the following conditions:

  • Major Depressive Disorder (MDD): This is the main condition for which citalopram is prescribed[9].
  • Anxiety Disorders: Including Generalized Anxiety Disorder (GAD), Social Phobia (SP), Panic Disorder (PD), and Separation Anxiety Disorder (SAD)[5].
  • Autism Spectrum Disorders (ASD): Specifically for treating repetitive behaviors in children with autism[6].
  • Cocaine Dependence: Research is being conducted on citalopram’s potential in treating cocaine addiction[7].

How Does Citalopram Work?

Citalopram works by increasing the levels of a neurotransmitter called serotonin in the brain. Serotonin is a chemical messenger that helps regulate mood, emotions, and other functions. By blocking the reuptake (reabsorption) of serotonin, citalopram allows more serotonin to remain available in the brain, which can help improve mood and reduce symptoms of depression and anxiety[8].

Dosage and Administration

The dosage of citalopram can vary depending on the condition being treated and the individual patient. Some common dosages include:

  • For adults with depression: 20-40 mg per day[1][2]
  • For children with autism (as studied): Up to 20 mg per day[6]
  • For anxiety disorders in adolescents: Starting at 5 mg per day, potentially increasing to 20 mg per day[5]

It’s important to note that dosages should always be determined by a healthcare professional based on individual patient needs and responses.

Effectiveness of Citalopram

Several studies have shown citalopram to be effective in treating various conditions:

  • For depression: Citalopram has been shown to improve symptoms of depression, as measured by standardized scales like the Montgomery-Asberg Depression Rating Scale (MADRS)[9].
  • For anxiety disorders: Research suggests that citalopram can be effective in reducing symptoms of anxiety in adolescents[5].
  • For autism: Studies are ongoing to determine if citalopram can help reduce repetitive behaviors in children with autism spectrum disorders[6].

Potential Side Effects

Like all medications, citalopram can cause side effects. Common side effects may include:

  • Nausea
  • Dry mouth
  • Drowsiness
  • Insomnia (difficulty sleeping)
  • Changes in appetite or weight

More serious side effects, though rare, can occur. It’s important to discuss all potential side effects with your healthcare provider[5].

Use in Special Populations

Citalopram’s use has been studied in various populations:

  • Children and Adolescents: While not approved for use in all countries, citalopram has been studied for treating anxiety and autism-related behaviors in young people[5][6].
  • Patients with Short Bowel Syndrome: Research is being conducted to understand how citalopram is processed in the bodies of people with this condition[10].

Ongoing Research

Citalopram continues to be the subject of various research studies, including:

  • Its potential use in treating cocaine dependence[7].
  • Comparisons between citalopram and escitalopram in terms of their effects on brain activity[8].
  • Combinations with other medications to potentially enhance its antidepressant effects[9].

As with any medication, it’s crucial to consult with a healthcare professional before starting or changing any treatment regimen involving citalopram.

Aspect Details
Conditions Studied Depression, Anxiety disorders, Autism spectrum disorders, Cocaine dependence
Common Dosages 20-40 mg daily, with some studies using flexible dosing
Administration Methods Oral tablets, Liquid formulation
Study Designs Randomized controlled trials, Double-blind studies, Bioequivalence studies
Comparison Medications Escitalopram, Placebo, Combination therapies (e.g., Pipamperone)
Primary Outcome Measures Changes in depression/anxiety scores, Reduction in repetitive behaviors, Cocaine use reduction
Safety Assessments Adverse events monitoring, Tolerability evaluations
Special Populations Adolescents, Children with autism
Neuroimaging Techniques fMRI to assess brain activity changes

FAQ

  • What is Citalopram used for in clinical trials? Citalopram is studied in clinical trials for various conditions, including major depressive disorder, anxiety disorders in adolescents, autism spectrum disorders, and cocaine dependence. It is also compared to other medications like Escitalopram for effectiveness in treating these conditions.
  • How is Citalopram administered in these trials? Citalopram is typically administered orally in tablet or liquid form. Dosages vary depending on the study, but common doses range from 20 mg to 40 mg per day. Some trials start with lower doses and gradually increase to higher doses over time.
  • What are some of the primary outcomes measured in Citalopram trials? Primary outcomes often include changes in depression or anxiety scores using standardized scales like the Montgomery-Asberg Depression Rating Scale (MADRS), improvements in repetitive behaviors in autism, and reduction in cocaine use for dependence studies. Safety and tolerability are also important outcomes in these trials.
  • Are there any special considerations for Citalopram use in children or adolescents? Yes, some trials specifically focus on the use of Citalopram in children and adolescents, particularly for anxiety disorders and autism spectrum disorders. These studies often use lower doses and carefully monitor for side effects and safety concerns specific to younger populations.
  • How does Citalopram compare to other similar medications in trials? Some trials compare Citalopram to other SSRIs like Escitalopram (Lexapro) or to combination therapies. These comparisons help determine if Citalopram is more effective, has fewer side effects, or offers any unique benefits compared to other treatment options for various conditions.

Ongoing Clinical Trials on Citalopram

  • Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

  • Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

  • Study on Dexamethasone for Patients with Moderate to Severe Depression: Evaluating Its Effectiveness with Mirtazapine, Citalopram, and Nortriptyline

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study on Citalopram for Patients with Reflux Hypersensitivity or Functional Heartburn Not Fully Helped by Proton Pump Inhibitors

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Temporarily Stopping Duloxetine, Sertraline, and Paroxetine in Patients with Hip or Knee Osteoarthritis Undergoing Surgery

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Testing Ulotaront Added to Antidepressants for Adults with Major Depressive Disorder Who Did Not Respond Well to Initial Treatment

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Poland Spain

  • Study of citalopram effectiveness in reducing chest pain for adults with achalasia

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

Glossary

  • Citalopram: A selective serotonin reuptake inhibitor (SSRI) antidepressant medication used to treat depression, anxiety disorders, and other mental health conditions.
  • Bioequivalence: The property of two drug products having the same biological effect in terms of the rate and extent of drug absorption when administered at the same dose.
  • SSRI: Selective Serotonin Reuptake Inhibitor, a class of antidepressant medications that work by increasing levels of serotonin in the brain.
  • Montgomery-Asberg Depression Rating Scale (MADRS): A commonly used scale to measure the severity of depressive episodes in patients with mood disorders.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs to determine their effectiveness.
  • Double-blind: A study design where neither the participants nor the researchers know who is receiving the active treatment and who is receiving the placebo.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly allocated to receive either the treatment under investigation or a placebo.
  • Anxiety disorder: A mental health condition characterized by persistent and excessive worry or fear about everyday situations.
  • Autism spectrum disorder: A developmental disorder that affects communication and behavior, often characterized by repetitive behaviors and difficulties with social interaction.
  • fMRI: Functional Magnetic Resonance Imaging, a neuroimaging technique used to detect brain activity by measuring changes in blood flow.

References

  1. https://clinicaltrials.gov/study/NCT01149980
  2. https://clinicaltrials.gov/study/NCT01149967
  3. https://clinicaltrials.gov/study/NCT00939835
  4. https://clinicaltrials.gov/study/NCT00940238
  5. https://clinicaltrials.gov/study/NCT01293838
  6. https://clinicaltrials.gov/study/NCT00086645
  7. https://clinicaltrials.gov/study/NCT01535573
  8. https://clinicaltrials.gov/study/NCT00825825
  9. https://clinicaltrials.gov/study/NCT00672659
  10. https://clinicaltrials.gov/study/NCT00876226